207 related articles for article (PubMed ID: 37819557)
21. Targeted downregulation of dMyc restricts neurofibrillary tangles mediated pathogenesis of human neuronal tauopathies in Drosophila.
Chanu SI; Sarkar S
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2111-2119. PubMed ID: 28529046
[TBL] [Abstract][Full Text] [Related]
22. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
Rodríguez-Navarro JA; Rodríguez L; Casarejos MJ; Solano RM; Gómez A; Perucho J; Cuervo AM; García de Yébenes J; Mena MA
Neurobiol Dis; 2010 Sep; 39(3):423-38. PubMed ID: 20546895
[TBL] [Abstract][Full Text] [Related]
23. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.
Reilly P; Winston CN; Baron KR; Trejo M; Rockenstein EM; Akers JC; Kfoury N; Diamond M; Masliah E; Rissman RA; Yuan SH
Neurobiol Dis; 2017 Oct; 106():222-234. PubMed ID: 28610892
[TBL] [Abstract][Full Text] [Related]
24. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
25. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies.
de Silva R; Lashley T; Gibb G; Hanger D; Hope A; Reid A; Bandopadhyay R; Utton M; Strand C; Jowett T; Khan N; Anderton B; Wood N; Holton J; Revesz T; Lees A
Neuropathol Appl Neurobiol; 2003 Jun; 29(3):288-302. PubMed ID: 12787326
[TBL] [Abstract][Full Text] [Related]
26. The Role of Tau Proteoforms in Health and Disease.
Waheed Z; Choudhary J; Jatala FH; Fatimah ; Noor A; Zerr I; Zafar S
Mol Neurobiol; 2023 Sep; 60(9):5155-5166. PubMed ID: 37266762
[TBL] [Abstract][Full Text] [Related]
27. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
28. Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models.
Sarkar S
J Genet; 2018 Jul; 97(3):783-793. PubMed ID: 30027909
[TBL] [Abstract][Full Text] [Related]
29. Tau and axonopathy in neurodegenerative disorders.
Higuchi M; Lee VM; Trojanowski JQ
Neuromolecular Med; 2002; 2(2):131-50. PubMed ID: 12428808
[TBL] [Abstract][Full Text] [Related]
30. Targeting tauopathy with engineered tau-degrading intrabodies.
Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
[TBL] [Abstract][Full Text] [Related]
31. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.
Fox LM; William CM; Adamowicz DH; Pitstick R; Carlson GA; Spires-Jones TL; Hyman BT
J Neuropathol Exp Neurol; 2011 Jul; 70(7):588-95. PubMed ID: 21666499
[TBL] [Abstract][Full Text] [Related]
32. Tau and Axonal Transport Misregulation in Tauopathies.
Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
[TBL] [Abstract][Full Text] [Related]
33. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
Gallo JM; Noble W; Martin TR
Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
35. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N
Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846
[TBL] [Abstract][Full Text] [Related]
36. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
37. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.
Sudo H; Baas PW
Hum Mol Genet; 2011 Feb; 20(4):763-78. PubMed ID: 21118899
[TBL] [Abstract][Full Text] [Related]
38. Untangling the Tauopathy for Alzheimer's disease and parkinsonism.
Chang HY; Sang TK; Chiang AS
J Biomed Sci; 2018 Jul; 25(1):54. PubMed ID: 29991349
[TBL] [Abstract][Full Text] [Related]
39. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
40. Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy.
Luciani M; Montalbano M; Troncone L; Bacchin C; Uchida K; Daniele G; Jacobs Wolf B; Butler HM; Kiel J; Berto S; Gensemer C; Moore K; Morningstar J; Diteepeng T; Albayram O; Abisambra JF; Norris RA; Di Salvo TG; Prosser B; Kayed R; Del Monte F
Eur Heart J; 2023 May; 44(17):1560-1570. PubMed ID: 37122097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
